Commentary
Nature Genetics 40, 939 - 942 (2008)
doi:10.1038/ng0808-939
Putting science over supposition in the arena of personalized genomics
Colleen M McBride1, Sharon Hensley Alford2, Robert J Reid3, Eric B Larson3, Andreas D Baxevanis4 & Lawrence C Brody4
- Colleen M. McBride is at the Social and Behavioral Research Branch, National Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
- Sharon Hensley Alford is at the Henry Ford Hospital, Detroit, Michigan 48202, USA.
- Robert J. Reid and Eric B. Larson are at the Center for Health Studies, Group Health Cooperative, Seattle, Washington 98101, USA.
- Andreas D. Baxevanis and Lawrence C. Brody are at the Genome Technology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Correspondence to: Colleen M McBride1 e-mail: cmcbride@mail.nih.gov
Correspondence to: Lawrence C Brody4 e-mail: lbrody@helix.nih.gov
Abstract
We explore the process of going from genome discovery to evaluation of medical impact and discuss emerging challenges faced by the scientific community. The need to confront these challenges is heightened in a climate where unregulated genetic tests are being marketed directly to the general public1, 2. Specifically, we characterize the delicate balance involved in deciding when genomic discoveries such as gene-disease associations are 'ready' to be evaluated as potential tools to improve health. We recommend that a considerable research commitment be made now in order to successfully bridge the rapidly widening gap between gene-disease association research and the critical (but slower and more involved) investigations into public health and clinical utility. Lastly, we describe a large, ongoing, early-phase research project, the Multiplex Initiative, which is examining issues related to the utility of genetic susceptibility testing for common health conditions.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Regulatory T-cell development: is Foxp3 the decider?Nature Medicine News and Views (01 Mar 2007)
